Drug Trial Radar · NCT02531802
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
Last checked: Nov 20, 2026Latest source record: Sep 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
475
Actual
Start
Oct 2015
Primary completion
Jul 29, 2017
Study completion Jul 29, 2017
Sponsor
- Lead sponsor
- PATHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Scandinavian Biopharma AB; International Centre for Diarrhoeal Disease Research, Bangladesh
- First posted
- Aug 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.
Conditions
- Escherichia Coli Diarrhea
Interventions
ETVAXBiological
Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of: * Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg * E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I) * E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3) * E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5) * E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6) The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid.
dmLTBiological
Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
Bicarbonate BufferOther
Sodium bicarbonate buffer dissolved in 150 ml of potable water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum SeverityTime frame: 7 days after each vaccination (Day 7 and Day 21)
- Number and Percentage of Participants Experiencing Unsolicited Adverse Events Related to VaccineTime frame: 6 months ± 14 days after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
International Centre for Diarrheal Disease, Bangladesh (icddr,b)
Dhaka, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.